249 results match your criteria: "Centre Hospitalier de l'Université Laval Research Center[Affiliation]"
TEMPOUR: A Randomized Controlled Trial Assessing Perioperative Use of An Alpha-1-Blocker to Reduce Postoperative Urinary Retention Following Transanal Endoscopic Microsurgery Procedures.
Dis Colon Rectum
January 2025
Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Université Laval, Québec City, Canada.
Background: Transanal endoscopic microsurgery is a treatment option for a wide range of rectal lesions. Postoperative urinary retention is a frequently associated complication. Some studies have suggested that the use of alpha-1-blockers may reduce the risk of postoperative urinary retention after hernia and colorectal surgery, but evidence is lacking.
View Article and Find Full Text PDFPolygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction.
Breast Cancer Res
December 2024
Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus.
Background: The 313-variant polygenic risk score (PRS) provides a promising tool for clinical breast cancer risk prediction. However, evaluation of the PRS across different European populations which could influence risk estimation has not been performed.
Methods: We explored the distribution of PRS across European populations using genotype data from 94,072 females without breast cancer diagnosis, of European-ancestry from 21 countries participating in the Breast Cancer Association Consortium (BCAC) and 223,316 females without breast cancer diagnosis from the UK Biobank.
Evaluating the performance of the BOADICEA model in predicting 10-year breast cancer risks in UK Biobank.
J Natl Cancer Inst
December 2024
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Background: The BOADICEA model predicts breast cancer risk using cancer family history, epidemiological and genetic data. We evaluated its validity in a large prospective cohort.
Methods: We assessed model calibration, discrimination and risk classification ability in 217,885 women (6,838 incident breast cancers) aged 40-70 years old of self-reported White ethnicity with no previous cancer from the UK Biobank.
Liberal or Restrictive Transfusion Strategy in Aneurysmal Subarachnoid Hemorrhage.
N Engl J Med
December 2024
From Ottawa Hospital Research Institute, Ottawa (S.W.E., D.A.F., A.T., I.W., T.R., R.M., D.D., S.C.M., L.M.); the Department of Medicine, Division of Critical Care, Faculty of Medicine, University of Ottawa, Ottawa (S.W.E., L.M.); School of Epidemiology and Public Health University of Ottawa, Ottawa (S.W.E., D.A.F., L.M.); Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa (D.A.F., D.D., S.C.M.); George Institute for Global Health, Sydney (A.D., F.B., N.H., C.R.A., P.T.); Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW, Australia (A.D., N.H., C.R.A., E.F.); the Faculty of Medicine and Health, University of Sydney Northern Clinical School, St. Leonards, NSW, Australia (A.D., C.R.A.); Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia (A.D., A.U.); the Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal (M. Chassé); the Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal (M. Chassé); the Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Université Laval, Quebec, QC, Canada (A.F.T., F.L.); Population Health and Optimal Health Practice Research Unit, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC, Canada (A.F.T., F.L.); the Department of Anesthesia, Critical Care Medicine Service, Hôpital de L'Enfant-Jésus, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, QC, Canada (A.F.T., F.L.); the Department of Medicine, Faculty of Medicine, Université Laval, Quebec, QC, Canada (F.L.); the Department of Neurology and Neurosurgery, Division of Neurocritical Care, Emory University School of Medicine, Emory University Hospital and Grady Memorial Hospital, Atlanta (O.S.); the Department of Medicine, Division of Critical Care Medicine, Faculty of Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada (D.E.G.); the Division of Neurosurgery, Vancouver General Hospital, Vancouver, BC, Canada (G.R.); the Division of Neurosurgery, Department of Surgery, the University of British Columbia, Vancouver, Canada (G.R.); Neurocritical Care and Anesthesia, Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Toronto (M. Chapman); McGill University, Montreal (M.H.); the Departments of Critical Care Medicine and Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada (A.K.); Nepean Clinical School, University of Sydney, Sydney (I.S.); the Department of Clinical Medicine, Macquarie University, Sydney (I.S.); the Critical Care and Trauma Division, the George Institute for Global Health, Sydney (I.S.); the Department of Intensive Care and Hyperbaric Medicine, the Alfred, Melbourne, VIC, Australia (A.U.); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada (D.J.K.); the Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada (R.Z.); the Department of Medical Oncology/Hematology and the Paul Albrechtsen Research Institute, Cancer Care Manitoba, Winnipeg, Canada (R.Z.); the Department of Anesthesiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada (F.D.); Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada (F.D.); the Department of Medicine, Division of Neurology, School of Medicine, Queen's University, Kingston, ON, Canada (J.G.B.); Department of Critical Care Medicine, School of Medicine, Queen's University, Kingston, ON, Canada (J.G.B.); the Intensive Care Unit, Prince of Wales Hospital, Randwick, NSW, Australia (G.S.); the Department of Intensive Care, Royal Brisbane and Women's Hospital, Herston, QLD, Australia (J.B.); University of Queensland, Brisbane, Australia (J.B.); the Department of Adult Intensive Care, Island Health Authority, Victoria, BC, Canada (G.W.); University of Colorado School of Medicine, Aurora (L.C.); the Department of Surgery, Division of Neurosurgery, Dalhousie University, Halifax, NS, Canada (G.P.); QEII Health Sciences Centre, Halifax, NS, Canada (G.P.); Lewis Katz School of Medicine, Temple University, Philadelphia (L.K.); Rush University Medical Center, Chicago (L.K.); Royal North Shore Hospital, Sydney (F.B.); the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto (D.C.S.); the Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto (D.C.S.); the Kirby Institute, University of New South Wales, Kensington, Australia (C.R.A.); the Department of Surgery, Division of Neurosurgery, Faculty of Medicine, University of Ottawa, Ottawa (J.S.); Canadian Blood Services, Edmonton, AB, Canada (J.A.); the Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada (J.A.); and Physical Medicine and Rehabilitation, Bruyere Continuing Care, Ottawa (S.C.M.).
Background: The effect of a liberal red-cell transfusion strategy as compared with a restrictive strategy in patients during the critical care period after an aneurysmal subarachnoid hemorrhage is unclear.
Methods: We randomly assigned critically ill adults with acute aneurysmal subarachnoid hemorrhage and anemia to a liberal strategy (mandatory transfusion at a hemoglobin level of ≤10 g per deciliter) or a restrictive strategy (optional transfusion at a hemoglobin level of ≤8 g per deciliter). The primary outcome was an unfavorable neurologic outcome, defined as a score of 4 or higher on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability) at 12 months.
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections.
N Engl J Med
November 2024
From the Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (N.D.), Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (A.R.), the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (R. Pinto); the Department of Infectious Diseases, Monash University, Clayton, Melbourne, VIC, Australia (B.A.R.), the Department of Intensive Care, Monash Medical Centre, Melbourne, VIC, Australia (Y.S.); the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand (R. Parke); the Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada (D.C.); the Intensive Care Department, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.A.); the Department of Critical Care Medicine, Queen's University, Kingston, ON, Canada (J. Muscedere), the Department of Critical Care Medicine, Royal Columbian Hospital, Vancouver, BC, Canada (S. Reynolds), Critical Care Medicine, Capital District Health Authority, Dalhousie University, Halifax, NS, Canada (R.H.); Monash Medical Centre, Clayton, VIC, Australia (D.B.D.); Critical Care Medicine, Auckland City Hospital, New Zealand (C. McArthur), the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand. (S. McGuinness); the Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, and Faculty of medicine, Ramat-Aviv, Tel-Aviv, Israel (D.Y.); Infectious Diseases, University Health Network, University of Toronto, Toronto (B.C.); Critical Care Medicine, North York General Hospital, Toronto (A.G., P.S.), Infectious Diseases, North York General Hospital, Toronto (P. Das), Critical Care Medicine, Mount Sinai Hospital, Unity Health Toronto, Toronto (M. Detsky), the Department of Medicine, University of Toronto, Toronto (A.M.); Sinai Health, Division of General Internal Medicine, Toronto, Toronto (M.F.), Infectious Diseases, Michael Garron Hospital, University of Toronto, Toronto (J.E.P.), Infectious Diseases, Michael Garron Hospital, Toronto (C. Kandel), Critical Care Medicine and Infectious Diseases, University of Alberta, Edmonton, Canada (W.S.), Department of Critical Care Medicine, University of Alberta and Alberta Health Services, Edmonton, Canada (S.M.B.), the Department of Medicine, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (N.S.), the Department of Anaesthesia, Hamilton General Hospital, McMaster University, Hamilton, ON, Canada (E.B.-C.), the Faculty of Health Sciences, Hamilton General Hospital, McMaster University, Hamilton, ON, Canada (R.W.), the Departments of Surgery and Critical Care, McGill University Health Center, Montreal (K.K.); the Departments of Infectious Diseases and Pathology, Middlemore hospital, University of Auckland, New Zealand (S. Morpeth), Organ Donation New Zealand, New Zealand Blood Service, Auckland, New Zealand (A. Kazemi), Intensive Care Medicine, Middlemore Hospital, Auckland, New Zealand (A.W.); the Division of Infectious Diseases, Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa (D.R.M.), the Department of Medicine, Ottawa Hospital, University of Ottawa, Ottawa (L.M.), Niagara Health Knowledge Institute, Niagara Health, St. Catharines, ON, Canada (J.T.), the Department of Medicine, Université de Sherbrooke, QC, Canada (F. Lamontagne); the Department of Microbiology and Infectious Diseases, Université de Sherbrooke, QC, Canada (A.C.), Surgery and Critical Care Medicine, Unity Health Toronto, University of Toronto, Toronto (J. Marshall); Critical Care and Medicine, Unity Health Toronto-St. Michael's Hospital, University of Toronto, Toronto (J.O.F.), Critical Care Medicine, Unity Health Toronto, Toronto (R.C.), the Department of Medicine, Unity Health Toronto, Toronto (M. Downing), the Department of Medicine, Infectious Diseases, Trillium Health Partners, University of Toronto, Toronto (C.G.); the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia (J.D.); the Division of Critical Care, Department of Medicine, McMaster University, Hamilton, ON, Canada (E.D.), St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada (J.N.), the Department of Medicine (Infectious Diseases), Queen's University, Kingston, ON, Canada (G.E.); the Department of Medicine, King Faisal Specialist Hospital and Research Center, Al Faisal University, Jeddah, Saudi Arabia (B.A.), the Department of Pathology and Laboratory Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (S.A.); the Department of Medicine, University of Western Ontario, London, Canada (C. Martin); the Department of Medicine, London Health Sciences Centre, London, ON, Canada (S.E.), the Department of Medicine, Western University, London, ON, Canada (I.B.), the Department of Medicine, Université Laval, Quebec, QC, Canada (F. Lauzier), the Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Université Laval, Quebec, QC, Canada (A.T.), the Population Health and Optimal Health Practice Research Unit, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec, QC, Canada (A.T.), the Department of Critical Care, University of Calgary Cumming School of Medicine, Calgary, AB, Canada (H.T.S.), the Department of Medicine, University of Calgary and Alberta Health Services (Calgary), Calgary, AB, Canada (J.C.), the Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montreal (E.G.M.), the Division of Infectious Diseases, Department of Medicine, McGill University, Montreal (T.C.L.); the Department Infectious Diseases, St. George Hospital, UNSW Medicine and Health, Sydney (R.S.); the Divisions of Infectious Diseases and Medical Microbiology, University of British Columbia, Vancouver, Canada (J.G.); the Intensive Care Unit, Rabin Medical Centers, Tel Aviv University, Tel Aviv, Israel (I.K.); the Intensive Care Research Programme, Medical Research Institute of New Zealand, Wellington, New Zealand (P.Y.), Medical Research Institute of New Zealand, Wellington, New Zealand. (C.L.); the Department of Infectious Diseases, Redcliffe Hospital, Redcliffe, QLD, Australia (K.O.), Infectious Diseases, Redcliffe Hospital, University of Queensland, Redcliffe, Australia (M.E.), Infectious Diseases, Sunshine Coast University Hospital, Sunshine Coast University Hospital, Birtinya, QLD, Australia (K.C.); Medicine, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal (P.A.); the Department of Anaesthesia, Rotorua Hospital, Rotorua, New Zealand (U.B.); Infectious Diseases, William Osler Health System, Brampton, ON, Canada (T. Havey), Critical Care Medicine, William Osler Health System, Brampton, ON, Canada (A.B.); the Department of Intensive Care Medicine, Bern University Hospital, University of Bern, Bern, Switzerland (J.P.); Brantford General Hospital, McMaster University, Brantford, ON, Canada (B.R.); the Intensive Care Unit, Fiona Stanley Hospital, University of Western Australia, Murdoch, WA, Australia (E.L.); the Department of Medicine, University of Manitoba, Winnipeg, Canada (S.L.), the Division of Critical Care Medicine and Infectious Diseases, Health Sciences Centre, University of Manitoba, Winnipeg, Canada (A. Kumar), the Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada (R.Z.); the Infectious Diseases Unit, Sheba Medical Center, Ramat Gan, Israel (T. Hoffman); the Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. (D.P.); Infectious Diseases, Memorial University, St. John's, NL, Canada (P. Daley); General and Subspecialty Medicine, Grampians Health Ballarat, Ballarat, VIC, Australia (R.J.C.); Service des soins intensifs, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal (E.C.), Critical Care Medicine, CIUSSS MCQ CHAUR, University of Montreal, Montreal (J.-F.N.); Clinical Microbiology and Infection Prevention and Control, Auckland Hospital, Auckland, New Zealand (S. Roberts); the Department of Intensive Care Medicine, Frankston Hospital, Frankston, VIC, Australia (R.T.), the Department of Intensive Care Medicine, Monash University, Melbourne, VIC, Australia (S.G.); the Department of Critical Care, Island Health Authority, Royal Jubilee Hospital, British Columbia, Victoria, Canada (G.W.); Infectious Diseases, Wollongong Hospital, Wollongong, NSW, Australia (O.S.), Infectious Diseases, Wollongong Hospital, University of Wollongong, Wollongong, NSW, Australia (S. Miyakis); the Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, Canada (P. Dodek), Infectious Diseases, Richmond Hospital, Richmond, BC, Canada (C. Kwok), and the Interdepartmental Division of Critical Care Medicine, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (R.A.F.).
Background: Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain.
Methods: In a multicenter, noninferiority trial, we randomly assigned hospitalized patients (including patients in the intensive care unit [ICU]) who had bloodstream infection to receive antibiotic treatment for 7 days or 14 days.
Use of opioids and opioid alternatives during general anesthesia: a pan-Canadian survey among anesthesiologists.
Can J Anaesth
December 2024
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Purpose: While there is limited patient-centred evidence (i.e., evidence that is important for patients and end-users) to inform the use of pharmacologic opioid minimization strategies (i.
View Article and Find Full Text PDFShifting Balance of the Risk-Benefit of Restrictive Transfusion Strategies in Neurocritically Ill Patients-Is Less Still More?
JAMA
November 2024
Population Health and Optimal Health Practices Unit, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Québec, Canada.
Frequency of Screening and Spontaneous Breathing Trial Techniques: A Randomized Clinical Trial.
JAMA
December 2024
Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts.
Article Synopsis
- The study investigates how often to screen critically ill adults on ventilators and the best method for conducting spontaneous breathing trials (SBT) to successfully extubate them.
- It involves a randomized clinical trial with 797 participants who required mechanical ventilation, comparing once-daily and more frequent screenings alongside two SBT techniques: pressure-supported and T-piece.
- Results show no significant differences in the time to successful extubation based on screening frequency or SBT technique, indicating that both methods may be similarly effective.
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
J Nucl Med
November 2024
Oncology Axis, CHU de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.
Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to determine the prevalence of IIH and RPT eligibility in mCRPC patients through a triple-tracer PET imaging strategy. This was a multisite prospective observational study in which mCRPC patients underwent both F-FDG and Ga-prostate-specific membrane antigen (PSMA)-617 PET/CT scans.
View Article and Find Full Text PDFThe association of antiplatelet agents with mortality among patients with non-COVID-19 community-acquired pneumonia: a systematic review and meta-analysis.
Res Pract Thromb Haemost
July 2024
Section of Critical Care, Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Article Synopsis
- Community-acquired pneumonia (CAP) can lead to serious inflammatory and thrombotic responses, and the use of antiplatelet agents may positively influence patient outcomes, although their impact on non-COVID-19 CAP is unclear.
- A systematic review and meta-analysis examined the effects of antiplatelet agents on mortality in hospitalized patients with non-COVID-19 CAP, analyzing data from observational studies and randomized controlled trials (RCTs).
- The findings suggest that antiplatelet agents are linked to lower mortality in observational studies, but the evidence from RCTs is inconclusive and overall trust in the results is low due to potential biases.
Prevalence of Oral Human Papillomavirus Infection Among Urban Gay, Bisexual, and Other Men Who Have Sex With Men in Canada, 2017-2019.
J Infect Dis
November 2024
MAP Centre for Urban Health Solutions, Unity Health Toronto, Toronto, Ontario, Canada.
Background: Oral human papillomavirus (HPV) infections are a leading cause of oropharyngeal cancers. In 2015 and 2016, HPV vaccines became publicly funded for gay, bisexual, and other men who have sex with men (GBM) under 27 years of age in most Canadian provinces.
Methods: Between 2017 and 2019, sexually active GBM in Montreal, Toronto, and Vancouver were recruited through respondent-driven sampling.
Barriers, Solutions, and Opportunities for Adapting Critical Care Clinical Trials in the COVID-19 Pandemic.
JAMA Netw Open
July 2024
Department of Critical Care, University of Calgary, Calgary, Alberta, Canada.
Article Synopsis
- The COVID-19 pandemic significantly disrupted clinical trials globally, leading to issues such as premature closures and compromised trial integrity, necessitating changes in research protocols.
- The study aimed to assess challenges faced during interrupted critical care trials, identifying barriers and developing strategies for future trials based on input from principal investigators and project coordinators.
- Results indicated that major challenges included the prioritization of COVID-19 studies and restrictions on hospital visitation, while participants offered various solutions and suggestions to enhance trial conduct moving forward.
Duration of Postvaccination Neutralizing Antibodies to SARS-CoV-2 and Medication Effects: Results from the Safety and Immunogenicity of COVID-19 Vaccination in Systemic Immune-Mediated Inflammatory Diseases Cohort Study.
ACR Open Rheumatol
September 2024
McGill University, Montreal, Québec, Canada.
Objective: In the face of the ongoing circulation of SARS-CoV-2, the durability of neutralization post-COVID-19 vaccination in immune-mediated inflammatory disease (IMID) is a key issue, as are the effects of medications.
Methods: Adults (n = 112) with inflammatory bowel disease, psoriasis/psoriatic arthritis, rheumatoid arthritis, spondylarthritis, and systemic lupus were recruited from participating Canadian medical centers from 2021 to 2023. We focused on log-transformed neutralization (lentivirus methods) as a continuous outcome, with separate models for wild-type and Omicron strains BA.
Background: Clinical trials suggest that therapeutic-dose heparin may prevent critical illness and vascular complications due to COVID-19, but knowledge gaps exist regarding the efficacy of therapeutic heparin including its comparative effect relative to intermediate-dose anticoagulation.
Objectives: The authors performed 2 complementary secondary analyses of a completed randomized clinical trial: 1) a prespecified per-protocol analysis; and 2) an exploratory dose-based analysis to compare the effect of therapeutic-dose heparin with low- and intermediate-dose heparin.
Methods: Patients who received initial anticoagulation dosed consistently with randomization were included.
Menopause and Estrogen Associations With Gut Barrier, Microbial Translocation, and Immune Activation Biomarkers in Women With and Without HIV.
J Acquir Immune Defic Syndr
July 2024
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
Article Synopsis
- Estrogens might help protect the gut barrier and lower immune activation in women with HIV, especially during the menopausal transition.
- A study measured gut-related biomarkers in 77 women, with 43 having HIV, over approximately 13 years to understand the effects of menopause and estradiol levels.
- Results showed that HIV-positive women had increased immune activation during menopause, with a decrease in activation after the transition, suggesting that lower estrogen levels could contribute to this heightened immune response.
Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation.
N Engl J Med
July 2024
From From the Departments of Medicine (D.C., G.G., W.A., M.M., E.D., J.C.D., J.L.Y.T., B. Rochwerg, T.K.), Health Research Methods, Evidence, and Impact (D.C., N.Z., G.G., D.H.-A., G.R., W.A., M.M., L.H., F.C., J.C.D., B. Rochwerg, F.X., L.T.), and Family Medicine (M.V.), McMaster University, Hamilton, ON, the Department of Medicine, University of British Columbia, Vancouver, BC (B.D.), Population Health and Optimal Health Practice Research Unit, Centre Hospitalier Universitaire de Québec, Université Laval Research Center, Quebec, QC (F. Lauzier), St. Joseph's Healthcare Hamilton Research Institute, Hamilton, ON (D.C., F.C., G.G., L.S., L.T., N.Z.), Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto (J. Marshall, K.B., A. Goffi, M.E.W., R.F., N.K.J.A., S.M.); Queen's University, Kingston, ON (J. Muscedere), the Department of Medicine, Critical Care, University of Ottawa, Ottawa (S.E.), Dalhousie University, Halifax, NS (R.H., O.L.), Niagara Health, St. Catharines, ON (E.D., J.L.Y.T.), Université de Sherbrooke, Sherbrooke, QC (F. Lamontagne, F.D., C.S.A.), Brantford General Hospital, Brantford, ON (B. Reeve), North York General Hospital, Toronto (A. Geagea), the Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB (D.N., K.F.), the University of Manitoba, Winnipeg (G.V.-G., R.Z.), Royal Jubilee Hospital, Victoria, BC (D.O., G.W.), Unity Health Toronto-St. Michael's Hospital, Toronto (K.B., A. Goffi), Vancouver General Hospital, Vancouver, BC (W.H.), Nanaimo Regional General Hospital, Nanaimo, BC (D.F.), the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto (R.F., N.K.J.A.), Western University, London, ON (I.B., T.M.), William Osler Hospital, Brampton, ON (A.B., S.T.), Mount Sinai Hospital, Toronto (S.M.), Cambridge Memorial Hospital, Cambridge, ON (I.M.), Centre Hospitalier de l'Université de Montréal (E.C.) and Hôpital du Sacré-Coeur de Montréal (E.C., Y.A.C.), University of Montreal (D.W.), Montreal, Université Laval, Quebec, QC (P.A.), the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton (O.G.R., V.L.), Meakins-Christie Laboratories and Translational Research in Respiratory Diseases Program, Research Institute of the McGill University Health Centre (A.S.K.), and the Department of Critical Care, McGill University (A.S.K., K.K.), Montreal, the Ottawa Hospital Research Institute, Ottawa (S. Kanji), the Department of Medicine, University of Saskatchewan, and the Department of Critical Care, Saskatchewan Health Authority, Regina (E.S.), Royal Columbia Hospital, New Westminster, BC (S.R.), Centre Intégré Universitaire de Santé et de Services Sociaux de l'Est-de-l'Île-de-Montréal, Hôpital Maisonneuve-Rosemont, Montreal (F.M.), Université Laval, Faculté de Médecine, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (F. Lellouche), the Department of Medicine, Windsor Regional Hospital, Windsor, ON (A.R.), Grand River Hospital, Kitchener, ON (P.H.), St. Joseph's Hospital, Toronto (R.C.), St. John Regional Hospital, St. John, NB (M.T.) - all in Canada; the University of Melbourne, Melbourne, VIC (A.D.); the George Institute for Global Health, Faculty of Medicine and Health, University of New South Wales (M.H., J. Myburgh, S. Knowles, N.H., B.V., D.R., L.B., S.F.) and St. George Hospital (J. Myburgh), Sydney, Royal Melbourne Hospital, Melbourne, VIC (K.M.B.), and the University of Adelaide, Adelaide, SA (M.C., A.P.) - all in Australia; King Abdullah International Medical Research Center and King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia (Y.M.A.); King's College London (M.O.) and School of Public Health, Faculty of Medicine, Imperial College (S.F.), London; Medical Research Institute of New Zealand, Wellington, New Zealand (P.Y.); the Department of Anesthesia, Critical Care Medicine, and Pain Medicine, Kuwait Extracorporeal Life Support Program, Al-Amiri Hospital, Ministry of Health, Kuwait City, Kuwait (A.A.-F.); Pontifical Catholic University, Belo Horizonte, Brazil (G.R.); the University of Nebraska Medical Center, Omaha (D.J.); the Department of Pulmonary and Critical Care Medicine, Maroof International Hospital, Islamabad, Pakistan (M.I.); and Midwestern University, College of Pharmacy, Glendale, AZ (J.F.B.).
Article Synopsis
- A study was conducted to evaluate the effects of the proton-pump inhibitor pantoprazole on critically ill patients undergoing invasive ventilation, comparing it to a placebo.
- The trial included 4,821 patients and found that pantoprazole significantly reduced the incidence of clinically important upper gastrointestinal bleeding compared to placebo (1.0% vs. 3.5%).
- However, there was no significant difference in overall mortality rates at 90 days between the pantoprazole group (29.1%) and the placebo group (30.9%).
Liberal or Restrictive Transfusion Strategy in Patients with Traumatic Brain Injury.
N Engl J Med
August 2024
From the Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine (A.F.T., M.V., M.S.-O., F. Lauzier), the Department of Social and Preventive Medicine (L.M.), the Department of Surgery, Division of Neurosurgery (P.L.B.), the Department of Medicine (V.L., F. Lauzier), and the Department of Family and Emergency Medicine (M.S.-O.), Faculty of Medicine, Université Laval, the Population Health and Optimal Health Practice Unit, Centre Hospitalier Universitaire de Québec-Université Laval Research Center (A.F.T., L.C., M.-P.P., X.N., L.M., P.L.B., M.V., M.S.-O., O.C., F. Lauzier), and the Department of Anesthesia, Critical Care Medicine Service, Hôpital de L'Enfant-Jésus, Centre Hospitalier Universitaire de Québec-Université Laval (A.F.T., F. Lauzier), Quebec City, QC, Ottawa Hospital Research Institute (D.A.F., S.W.E., T.R., M.T., A.T.), the School of Epidemiology and Public Health (D.A.F., S.W.E., T.R., M.T., A.T.), the Division of Critical Care (S.W.E.), the Division of Hematology (A.T.), and the Division of Palliative Care (P.C.H.), the Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montreal (L.C.), the Department of Internal Medicine (R.Z.), the Departments of Surgery and of Human Anatomy and Cell Science (F.Z., A.G.), Rady Faculty of Health Sciences, and the Biomedical Engineering Program, Faculty of Engineering (F.Z.), University of Manitoba, and the Department of Medical Oncology-Hematology and the Paul Albrechtsen Research Institute, CancerCare Manitoba (R.Z.), Winnipeg, the Department of Critical Care Medicine, Sunnybrook Health Sciences Center and Sunnybrook Research Institute (D.C.S., N.K.J.A.), and the Interdepartmental Division of Critical Care Medicine, University of Toronto (D.C.S., N.K.J.A., A.R., K.E.A.B., J.M.), Toronto, the Departments of Critical Care Medicine and Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (A.K.), the Departments of Medicine and of Epidemiology and Biostatistics, Western University, London, ON (I.B.), the Departments of Surgery and Critical Care Medicine, McGill University Health Centre, Montreal (K.K.), the Department of Medicine, Faculty of Medicine, and Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC (F. Lamontagne), the Department of Surgery, Division of Neurosurgery, McMaster University, Hamilton Health Sciences, Hamilton, ON (A.A.), the Department of Anesthesia, St. Michael's Hospital, University of Toronto (A.R.), the Applied Health Research Centre, Li Ka Shing Knowledge Institute, and the Department of Critical Care, Unity Health Toronto-St. Michael's Hospital (K.E.A.B., J.M.), Toronto, the Departments of Medicine (A.F.-R.) and Health Research Methods, Evidence and Impact (K.E.A.B.), McMaster University, Hamilton, ON, the Department of Medicine, Division of Critical Care Medicine, Faculty of Medicine, Vancouver General Hospital, University of British Columbia, Vancouver (D.E.G.), the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton (D.J.K.), Trauma Nova Scotia, Nova Scotia Health, and the Departments of Critical Care, Emergency Medicine, and Anesthesia and Surgery, Dalhousie University, Halifax (R.G.), the Department of Medicine, Division of Neurology, and the Department of Critical Care Medicine, School of Medicine, Queen's University, Kingston, ON (J.G.B.), the Department of Medicine, Centre Hospitalier de l'Université de Montréal, and the Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal (E.C., M.C.), Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de la Mauricie-et-du-Centre-du-Québec, Trois-Rivières (E.C.), the University of Saskatchewan, College of Medicine, and Saskatchewan Health Authority-Regina Area, Regina (E.S.), and Bruyère Research Institute, University of Ottawa, Ottawa (P.C.H.) - all in Canada; Usher Institute of Population Health Sciences (T.S.W., A.D.) and the Department of Anaesthesia, Critical Care, and Pain Medicine (T.S.W., A.D., J.R.), Edinburgh Medical School, University of Edinburgh, Edinburgh, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford (J.G.), the Department of Critical Care Medicine, Imperial College Healthcare NHS Trust, St. Mary's Hospital, London (V.G.R.), Cardiff University and the University of Wales Hospital, Cardiff (M.W.), Nottingham University Hospitals NHS Trust, Nottingham (D.H.), University Hospitals North Midlands-Royal Stoke Hospital, Stoke-on-Trent (S.K.), the Division of Anaesthesia, Addenbrooke's Hospital, University of Cambridge, Cambridge (F.Z.), James Cook University Hospital, Middlesbrough (J.W.), and the Walton NHS Foundation Trust (P.N.) and the Department of Intensive Care Medicine, Liverpool University Hospitals NHS (T.A.), Liverpool - all in the United Kingdom; Surgical Intensive Care Unit, Anesthesiology Division, Hospital das Clínicas, University of São Paulo Medical School (L.M.M.), and the Intensive Care Unit, Hospital de Amor de Nossa Senhora (L.S.S.) - both in São Paulo; the Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besançon, Besançon (S.P.-F.), Département Anesthésie Réanimation et Médecine Périopératoire, Centre Hospitalier Universitaire (CHU) de Clermont-Ferrand, Clermont-Ferrand (R.C.), Hôpital de Hautepierre, Service d'Anesthésie-Réanimation et Médecine Péri-Opératoire, Hôpitaux Universitaires de Strasbourg, Strasbourg (J.P.), and UR-UM103 IMAGINE, University of Montpellier, Division of Anesthesia and Critical Care, Pain, and Emergency Medicine, Nîmes University Hospital, Montpellier (C.R.) - all in France.
Background: The effect of a liberal transfusion strategy as compared with a restrictive strategy on outcomes in critically ill patients with traumatic brain injury is unclear.
Methods: We randomly assigned adults with moderate or severe traumatic brain injury and anemia to receive transfusion of red cells according to a liberal strategy (transfusions initiated at a hemoglobin level of ≤10 g per deciliter) or a restrictive strategy (transfusions initiated at ≤7 g per deciliter). The primary outcome was an unfavorable outcome as assessed by the score on the Glasgow Outcome Scale-Extended at 6 months, which we categorized with the use of a sliding dichotomy that was based on the prognosis of each patient at baseline.
Blood Pressure Management in Early Aneurysmal Subarachnoid Hemorrhage: A National Cross-Sectional Survey of Canadian Intensivists and Cerebrovascular Neurosurgeons.
Neurocrit Care
December 2024
Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Background: In aneurysmal subarachnoid hemorrhage (aSAH), rebleeding of the culprit aneurysm is associated with significant morbidity and mortality. Blood pressure reduction to specific target levels, with the goal of preventing rebleeding, has been a mainstay of care prior to definitively securing the aneurysm. Clinical practice guidelines have recently changed and no longer recommend specific blood pressure targets.
View Article and Find Full Text PDFWhy improved surveillance is critical for reducing maternal deaths in the United States: a response to the American College of Obstetricians and Gynecologists.
Am J Obstet Gynecol
August 2024
Division of Epidemiology and Biostatistics, Department of Obstetrics, Gynecology, and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ; Cardiovascular Institute of New Jersey and Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ; Environmental and Occupational Health Sciences Institute, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ.
Association Between Frailty and Head Impact Location After Ground-Level Fall in Older Adults.
J Emerg Med
May 2024
Centre Hospitalier Universitaire de Québec, Université Laval Research Center, Axe Santé des Populations et Pratiques Optimales en Santé, D'Estimauville, Québec, Québec, Canada; Université Laval, Québec, Québec, Canada.
Background: Mild traumatic brain injuries (TBIs) are highly prevalent in older adults, and ground-level falls are the most frequent mechanism of injury.
Objective: This study aimed to assess whether frailty was associated with head impact location among older patients who sustained a ground-level fall-related, mild TBI. The secondary objective was to measure the association between frailty and intracranial hemorrhages.
Chronically activated microglia in ALS gradually lose their immune functions and develop unconventional proteome.
Glia
July 2024
CERVO Research Centre, Laval University, Quebec City, Quebec, Canada.
Neuroinflammation and chronic activation of microglial cells are the prominent features of amyotrophic lateral sclerosis (ALS) pathology. While alterations in the mRNA profile of diseased microglia have been well documented, the actual microglia proteome remains poorly characterized. Here we performed a functional characterization together with proteome analyses of microglial cells at different stages of disease in the SOD1-G93A model of ALS.
View Article and Find Full Text PDFCorrigendum: Revisiting multi-omics-based predictors of the plasma triglyceride response to an omega-3 fatty acid supplementation.
Front Nutr
March 2024
Centre Nutrition, santé et société (NUTRISS)-Institut sur la nutrition et les aliments fonctionnels (INAF), Université Laval, Québec, QC, Canada.
[This corrects the article DOI: 10.3389/fnut.2024.
View Article and Find Full Text PDFA phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation.
Commun Med (Lond)
March 2024
CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada.
Background: High prostate eicosapentaenoic fatty acid (EPA) levels were associated with a significant reduction of upgrading to grade group (GG) ≥ 2 prostate cancer in men under active surveillance. We aimed to evaluate the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation.
Methods: A phase II double-blind randomized placebo-controlled trial was conducted in 130 men diagnosed with GG ≥ 2 prostate cancer and undergoing radical prostatectomy between 2015-2017 (Clinicaltrials.
Quality of life and cost-effectiveness of convalescent plasma compared to standard care for hospitalized COVID-19 patients in the CONCOR-1 trial.
Transfusion
April 2024
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Article Synopsis
- The CONCOR-1 trial was a study aimed at evaluating the cost-effectiveness and quality-of-life implications of using convalescent plasma as a treatment for hospitalized COVID-19 patients compared to standard care.
- The trial included 940 patients, with those receiving convalescent plasma incurring higher costs ($28,716) but showing similar quality-of-life scores to standard care patients ($24,258), indicating no significant benefit.
- Results suggested that convalescent plasma treatment was less effective and more expensive than standard care, questioning its viability as an alternative treatment in resource-limited health settings.*
Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.
medRxiv
March 2024
Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Background: Nineteen genomic regions have been associated with high-grade serous ovarian cancer (HGSOC). We used data from the Ovarian Cancer Association Consortium (OCAC), Consortium of Investigators of Modifiers of (CIMBA), UK Biobank (UKBB), and FinnGen to identify novel HGSOC susceptibility loci and develop polygenic scores (PGS).
Methods: We analyzed >22 million variants for 398,238 women.